Biomarkers and possible mechanisms of operational tolerance in kidney transplant patients

Immunological Reviews

Volumn 258, Issue 1, 2014, Pages 208-217

  Dugast, Emilie ^a,b   Chesneau, Mélanie ^a,d   Soulillou, Jean Paul ^a,b,c,d   Brouard, Sophie ^a,b,c,d  

^a Centre National de la Recherche Scientifique   (France)

^b CENTAURE Network   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE NANTES   (France)

Author keywords

Biomarker; Kidney transplantation; Operational tolerance

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; CORTICOSTEROID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

B LYMPHOCYTE; GRAFT RECIPIENT; HOMEOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; KIDNEY ALLOGRAFT; KIDNEY GRAFT; OPERATIONAL TRANSPLANT TOLERANCE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; ANIMAL; BLOOD; DRUG ADMINISTRATION; DRUG EFFECTS; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; KIDNEY TRANSPLANTATION; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL MARKERS; DRUG ADMINISTRATION SCHEDULE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 84893555723     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12156     Document Type: Review

References (94)

1. Morris PJ. Transplantation - a medical miracle of the 20th century. N Engl J Med 2004;351:2678-2680.
2. Nankivell BJ, Kuypers DRJ. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011;378:1428-1437.
3. Dantal J, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998;351:623-628.
4. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-2729.
5. Nankivell BJ, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326-2333.
6. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002;346:580-590.
7. Solez K, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007;7:518-526.
8. Soulillou JP, Giral M. Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation 2001;72:S89-S93.
9. Auchincloss H Jr. In search of the elusive Holy Grail: the mechanisms and prospects for achieving clinical transplantation tolerance. Am J Transplant 2001;1:6-12.
10. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953;172:603-606.
11. Sakaguchi S, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006;212:8-27.
12. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003;3:199-210.
13. Jovanovic V, Lair D, Soulillou J-P, Brouard S. Transfer of tolerance to heart and kidney allografts in the rat model. Transpl Int 2008;21:199-206.
14. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984;307:168-170.
15. Sykes M, Sachs DH. Mixed allogeneic chimerism as an approach to transplantation tolerance. Immunol Today 1988;9:23-27.
16. Ashton-Chess J, Brouard S, Soulillou J-P. Is clinical tolerance realistic in the next decade? Transpl Int 2006;19:539-548.
17. Larsen CP, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 2010;90:1528-1535.
18. Pilat N, Sayegh MH, Wekerle T. Costimulatory pathways in transplantation. Semin Immunol 2011;23:293-303.
19. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601-2614.
20. Stegall MD, et al. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss. Hepatology 1997;25:173-177.
21. Ballet C, et al. Humoral and cellular responses to influenza vaccination in human recipients naturally tolerant to a kidney allograft. Am J Transplant 2006;6:2796-2801.
22. Brouard S, et al. The natural history of clinical operational tolerance after kidney transplantation through twenty-seven cases. Am J Transplant 2012;12:3296-3307.
23. Roussey-Kesler G, et al. Clinical operational tolerance after kidney transplantation. Am J Transplant 2006;6:736-746.
24. Ashton-Chess J, Giral M, Brouard S, Soulillou J-P. Spontaneous operational tolerance after immunosuppressive drug withdrawal in clinical renal allotransplantation. Transplantation 2007;84:1215-1219.
25. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 2006;6:1774-1780.
26. Turka LA, Lechler RI. Towards the identification of biomarkers of transplantation tolerance. Nat Rev Immunol 2009;9:521-526.
27. Burlingham WJ, et al. Microchimerism linked to cytotoxic T lymphocyte functional unresponsiveness (clonal anergy) in a tolerant renal transplant recipient. Transplantation 1995;59:1147-1155.
28. Christensen LL, Grunnet N, Rüdiger N, Møller B, Birkeland SA. Indications of immunological tolerance in kidney transplantation. Tissue Antigens 1998;51:637-644.
29. Fischer T, Schobel H, Barenbrock M. Specific immune tolerance during pregnancy after renal transplantation. Eur J Obstet Gynecol Reprod Biol 1996;70:217-219.
30. Uehling DT, Hussey JL, Weinstein AB, Wank R, Bach FH. Cessation of immunosuppression after renal transplantation. Surgery 1976;79:278-282.
31. Zoller KM, Cho SI, Cohen JJ, Harrington JT. Cessation of immunosuppressive therapy after successful transplantation: a national survey. Kidney Int 1980;18:110-114.
32. Brouard S, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 2007;104:15448-15453.
33. Haynes LD, et al. Donor-specific indirect pathway analysis reveals a B-cell-independent signature which reflects outcomes in kidney transplant recipients. Am J Transplant 2012;12:640-648.
34. Newell KA, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest 2010;120:1836-1847.
35. Pallier A, et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int 2010;78:503-513.
36. Sagoo P, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010;120:1848-1861.
37. Atkinson AJ, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
38. Mengel M, et al. Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012;12:563-570.
39. Sis B, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010;10:464-471.
40. Ashton-Chess J, Giral M, Soulillou J-P, Brouard S. Using biomarkers of tolerance and rejection to identify high- and low-risk patients following kidney transplantation. Transplantation 2009;87:S95-S99.
41. Alizadeh AA, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
42. Kienzl K, et al. Proteomic profiling of acute cardiac allograft rejection. Transplantation 2009;88:553-560.
43. Naesens M, Sarwal MM. Molecular diagnostics in transplantation. Nat Rev Nephrol 2010;6:614-628.
44. Suárez-Alvarez B, et al. Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells. PLoS ONE 2010;5:e10192.
45. Allison SJ. Transplantation: integrative peptidomics identifies acute renal-transplant rejection biomarkers. Nat Rev Nephrol 2010;6:249.
46. Süsal C, Pelzl S, Döhler B, Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002;13:1650-1656.
47. Braudeau C, et al. Variation in numbers of CD4+CD25highFOXP3+ T cells with normal immuno-regulatory properties in long-term graft outcome. Transpl Int 2007;20:845-855.
48. Becker LE, et al. Cellular infiltrates and NFκB subunit c-Rel signaling in kidney allografts of patients with clinical operational tolerance. Transplantation 2012;94:729-737.
49. Ashton-Chess J, et al. Regulatory, effector, and cytotoxic T cell profiles in long-term kidney transplant patients. J Am Soc Nephrol 2009;20:1113-1122.
50. Mas VR, et al. Evaluation of gene panel mRNAs in urine samples of kidney transplant recipients as a non-invasive tool of graft function. Mol Med 2007;13:315-324.
51. Muthukumar T, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005;353:2342-2351.
52. VanBuskirk AM, et al. Human allograft acceptance is associated with immune regulation. J Clin Invest 2000;106:145-155.
53. Brouard S, et al. Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am J Transplant 2005;5:330-340.
54. Louis S, et al. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006;81:398-407.
55. Baeten D, et al. Phenotypically and functionally distinct CD8+ lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J Am Soc Nephrol 2006;17:294-304.
56. Braud C, et al. Immunosuppressive drug-free operational immune tolerance in human kidney transplant recipients: Part I. Blood gene expression statistical analysis. J Cell Biochem 2008;103:1681-1692.
57. Braudeau C, et al. Contrasted blood and intragraft toll-like receptor 4 mRNA profiles in operational tolerance versus chronic rejection in kidney transplant recipients. Transplantation 2008;86:130-136.
58. Moraes-Vieira PMM, et al. Differential monocyte STAT6 activation and CD4(+)CD25(+)Foxp3(+) T cells in kidney operational tolerance transplanted individuals. Hum Immunol 2010;71:442-450.
59. Lozano JJ, et al. Comparison of transcriptional and blood cell-phenotypic markers between operationally tolerant liver and kidney recipients. Am J Transplant 2011;11:1916-1926.
60. Danger R, et al. PARVG gene polymorphism and operational renal allograft tolerance. Transplant Proc 2012;44:2845-2848.
61. Moraes-Vieira PMM, et al. GATA3 and a dominant regulatory gene expression profile discriminate operational tolerance in human transplantation. Clin Immunol 2012;142:117-126.
62. Silva HM, et al. Preserving the B cell compartment favors operational tolerance in human renal transplantation. Mol Med 2012;18:733-743.
63. Danger R, et al. Upregulation of miR-142-3p in peripheral blood mononuclear cells of operationally tolerant patients with a renal transplant. J Am Soc Nephrol 2012;23:597-606.
64. Soulillou J-P, Giral M, Brouard S. Operational tolerance in kidney transplantation-improved terminology may enable more precise investigation. Transplantation 2013;96:e36-e38.
65. Groux H, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-742.
66. Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci USA 1992;89:421-425.
67. Levings MK, et al. Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med 2002;196:1335-1346.
68. Miyara M, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009;30:899-911.
69. Hilbrands R, Howie D, Cobbold S, Waldmann H. Regulatory T cells and transplantation tolerance. Immunotherapy 2013;5:717-731.
70. Kingsley CI, Nadig SN, Wood KJ. Transplantation tolerance: lessons from experimental rodent models. Transpl Int 2007;20:828-841.
71. Taubert R, et al. Enrichment of regulatory T cells in acutely rejected human liver allografts. Am J Transplant 2012;12:3425-3436.
72. Baecher-Allan C, Wolf E, Hafler DA. MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol 2006;176:4622-4631.
73. Loveland BE, McKenzie IF. Delayed-type hypersensitivity and allograft rejection in the mouse: correlation of effector cell phenotype. Immunology 1982;46:313-320.
74. Szczepanik M, et al. B-1 B cells mediate required early T cell recruitment to elicit protein-induced delayed-type hypersensitivity. J Immunol 2003;171:6225-6235.
75. Valujskikh A, et al. T cells reactive to a single immunodominant self-restricted allopeptide induce skin graft rejection in mice. J Clin Invest 1998;101:1398-1407.
76. Guillonneau C, et al. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2, 3-dioxygenase. J Clin Invest 2007;117:1096-1106.
77. Li XL, et al. Mechanism and localization of CD8 regulatory T cells in a heart transplant model of tolerance. J Immunol 2010;185:823-833.
78. Brauweiler AM, Cambier JC. Fc gamma RIIB activation leads to inhibition of signalling by independently ligated receptors. Biochem Soc Trans 2003;31:281-285.
79. Aiba Y, et al. BANK negatively regulates Akt activation and subsequent B cell responses. Immunity 2006;24:259-268.
80. Le Texier L, et al. Long-term allograft tolerance is characterized by the accumulation of B cells exhibiting an inhibited profile. Am J Transplant 2011;11:429-438.
81. Parker DC. T cell-dependent B cell activation. Annu Rev Immunol 1993;11:331-360.
82. Wahl SM, Rosenstreich DL. Role of B lymphocytes in cell-mediated immunity. I. Requirement for T cells or T-cell products for antigen-induced B-cell activation. J Exp Med 1976;144:1175-1187.
83. Huang B, et al. miR-142-3p restricts cAMP production in CD4+CD25- T cells and CD4+CD25+ TREG cells by targeting AC9 mRNA. EMBO Rep 2009;10:180-185.
84. Wood KJ, Goto R. Mechanisms of rejection: current perspectives. Transplantation 2012;93:1-10.
85. Li L, et al. A common peripheral blood gene set for diagnosis of operational tolerance in pediatric and adult liver transplantation. Am J Transplant 2012;12:1218-1228.
86. Martínez-Llordella M, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007;7:309-319.
87. Neudoerfl C, et al. The peripheral NK cell repertoire after kidney transplantation is modulated by different immunosuppressive drugs. Front Immunol 2013;4:46.
88. Doyle SL, O'Neill LAJ. Toll-like receptors: from the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. Biochem Pharmacol 2006;72:1102-1113.
89. Wu H, et al. Absence of MyD88 signaling induces donor-specific kidney allograft tolerance. J Am Soc Nephrol 2012;23:1701-1716.
90. Poirier N, et al. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med 2010;2:17ra10.
91. Heidt S, Hester J, Shankar S, Friend PJ, Wood KJ. B cell repopulation after alemtuzumab induction-transient increase in transitional B cells and long-term dominance of naïve B cells. Am J Transplant 2012;12:1784-1792.
92. Liu C, et al. B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nat Med 2007;13:1295-1298.
93. Noris M, et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 2007;18:1007-1018.
94. Porcheray F, et al. B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans. Am J Transplant 2009;9:2126-2135.